In Situ TCE: Targeting Previously Undruggable Solid Tumor Antigens via Tumor-Restricted T Cell Redirection

Calidi Biotherapeutics Inc. published this content on October 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 19:52 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]